Alumis (ALMS) News
NASDAQ: ALMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.16+0.19 (+2.73%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ALMS news summary
We found 2 recent headlines mentioning Alumis (ALMS): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, ALMS is up 2.73% at $7.16. The most recent story, "Alumis Reports Positive Phase 3 Data With Envudeucitinib", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Alumis headlines
- Alumis Reports Positive Phase 3 Data With Envudeucitinib(RTTNews) - Alumis (ALMS) announced envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWARD2, and the long-term extension ONWARD3. The company said the results reinforced…NasdaqALMS, ET
- Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresNew Phase 3 Data Demonstrates Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresGlobeNewswire